Last reviewed · How we verify
Doxazosin Mesylate, Extended Release
Doxazosin mesylate is an alpha-1 adrenergic receptor antagonist that relaxes smooth muscle in the prostate and bladder neck, improving urine flow and reducing symptoms of benign prostatic hyperplasia.
Doxazosin mesylate is an alpha-1 adrenergic receptor antagonist that relaxes smooth muscle in the prostate and bladder neck, improving urine flow and reducing symptoms of benign prostatic hyperplasia. Used for Benign prostatic hyperplasia, Hypertension.
At a glance
| Generic name | Doxazosin Mesylate, Extended Release |
|---|---|
| Also known as | Cardura XL |
| Sponsor | San Francisco Veterans Affairs Medical Center |
| Drug class | Alpha-1 adrenergic receptor antagonist |
| Target | Alpha-1 adrenergic receptor |
| Modality | Small molecule |
| Therapeutic area | Urology |
| Phase | Phase 2 |
Mechanism of action
By blocking alpha-1 adrenergic receptors, doxazosin mesylate decreases the muscle tone in the prostate and bladder neck, allowing for improved urine flow and reduced symptoms of benign prostatic hyperplasia. This is achieved through the relaxation of smooth muscle in these areas, which in turn reduces the resistance to urine flow.
Approved indications
- Benign prostatic hyperplasia
- Hypertension
Common side effects
- Dizziness
- Headache
- Fatigue
- Nausea
- Orthostatic hypotension
Key clinical trials
- A Randomized Controlled Trial of Doxazosin for Nightmares, Sleep Disturbance, and Non-Nightmare Clinical Symptoms in PTSD (PHASE2)
- Doxazosin for Psychostimulant Dependence (PHASE1, PHASE2)
- Black Education and Treatment of Hypertension (BEAT HTN) (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: